Hengrui Medicine gains approval for HRS-1301 clinical trial

Jiangsu Hengrui Medicine announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for clinical trials of HRS-1301 tablets. The drug, a Class 1 chemical medication developed independently by the company, is intended for the treatment of hyperlipidemia. Preclinical studies indicate HRS-1301 can effectively improve hyperlipidemia. Currently, no similar drugs have been approved globally. As of now, the cumulative R&D investment in HRS-1301 related projects is approximately RMB 18.36 million. The company cautioned that the drug development process is lengthy and subject to uncertainty, advising investors to exercise caution. Hengrui Medicine will actively advance the research project and fulfill its information disclosure obligations.